People

Keith T. Flaherty, MD, began his 5-year term as editor-in-chief of Clinical Cancer Research, a journal of the American Association for Cancer Research, on January 1. He succeeds Kenneth Anderson, MD. Flaherty is director of the Center for Targeted Therapies at Massachusetts General Hospital in Boston. His research focuses on understanding the molecular and clinical consequences of inhibiting oncogenes in melanoma. A pioneer in developing targeted therapies, he led early clinical trials on the development of vemurafenib (Zelboraf; Genentech) and trametinib (Mekinist; Novartis), as well as the trametinib/dabrafenib (Tafinlar; Novartis) combination.

Richard M. Goldberg, MD, a renowned gastrointestinal cancer expert, started his role as director of the West Virginia University Cancer Institute last month. He aims to strengthen research efforts and expand patient care in the state. Previously, Goldberg served as physician-in-chief of the James Cancer Hospital and associate director of The Ohio State University (OSU) Comprehensive Cancer Center in Columbus. In addition, he co-chairs the Society for Translational Oncology, participates in the CEO Roundtable on Cancer, and serves or has served on numerous editorial boards.

The Medical University of South Carolina named Gustavo W. Leone, PhD, director of the Hollings Cancer Center in Charleston, effective March 1. One of his goals is to boost programming and recruitment efforts at Hollings to help the center attain status as an NCI Comprehensive Cancer Center. Previously, Leone worked as director of the Solid Tumor Biology Program and as associate director for basic research at OSU. He conducts basic and translational research on how the disruption of critical cell-cycle pathways contributes to uncontrolled cell growth.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.